PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.40%
Both companies show declining cash positions (-13.40% vs TRVN's -26.34%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-13.40%
Cash + STI yoy ≥ 1.5x TRVN's -5.31%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.47%
≥ 1.5x TRVN's -4.91%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
8.92%
Below half TRVN's 18.27%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.91%
≥ 1.5x TRVN's 15.39%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-12.20%
≥ 1.5x TRVN's -4.82%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
25.71%
Less than half of TRVN's -41.03%. David Dodd sees a more disciplined AP approach or lower volume.
-32.96%
Higher Short-Term Debt Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56.33%
50-75% of TRVN's -98.26%. Bruce Berkowitz notes a more controlled liability line.
-28.78%
Similar yoy to TRVN's -29.73%. Walter Schloss sees parallel short-term liability strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.78%
Above 1.5x TRVN's -12.24%. Michael Burry sees a potential leverage warning sign.
1.95%
50-75% of TRVN's 2.69%. Bruce Berkowitz notes minimal new equity relative to competitor.
-3.92%
Below half TRVN's -9.74%. Michael Burry suspects major net losses or high dividends vs. competitor.
-19.50%
Less than half of TRVN's 114.64%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.72%
≥ 1.5x TRVN's -3.15%. David Dodd sees stronger capital base growth than competitor.
-12.20%
≥ 1.5x TRVN's -4.82%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-32.96%
Less than half of TRVN's 0.22%. David Dodd sees less overall debt expansion vs. competitor.
13.20%
Less than half of TRVN's 43.25%. David Dodd sees better deleveraging or stronger cash buildup than competitor.